Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAbbotts XIENCE V Continues to Outperform TAXUS with Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Abbott, 09/22/09
Long–term data presented from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market–leading XIENCE V Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS Express2 Paclitaxel–Eluting Coronary Stent System. At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p–value=0.003)*.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09
Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09
Sponsor
Article Search
Sponsor